[{"id":"060e7871-5a8c-4f16-a224-6a753b1ca603","acronym":"","url":"https://clinicaltrials.gov/study/NCT05859074","created_at":"2023-05-15T14:04:26.274Z","updated_at":"2024-07-02T16:35:19.241Z","phase":"Phase 1","brief_title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05859074","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MQ710"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/04/2023","start_date":" 05/04/2023","primary_txt":" Primary completion: 05/04/2028","primary_completion_date":" 05/04/2028","study_txt":" Completion: 05/04/2028","study_completion_date":" 05/04/2028","last_update_posted":"2024-02-15"}]